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Introduction
Airway afferent (sensory) nerves express a variety of recep-
tors and ion channels that, when acted upon by various
pharmacologic agents, modulate the activity of these
nerves. The induced changes in the activity of airway affer-
ent nerves, in turn, inform the central nervous system (CNS)
of a change in their immediate environment and, via reflex
pathways, modulate the parasympathetic (cholinergic and
noncholinergic) and sympathetic outflow to the airways. In
addition, airway afferent nerve activation is responsible for
initiating the cough reflex and serves to modulate breathing
pattern. Through these actions, the afferent nervous system
plays an important role in regulating the physiology of the
airways. Abnormalities in afferent nerve function arguably
contribute directly to the cause of certain airway patholo-
gies, and undeniably to the symptoms of virtually all airway
diseases. It may seem surprising, therefore, that our under-
standing of the pharmacology of airway afferent nerves is at
best rudimentary. This is probably explained by the difficulty
in reducing, in a scientific sense, airway afferent nerve
endings to an experimental design that is amenable to clas-
sical pharmacologic investigation.
In the present review studies are discussed that investi-
gated the direct actions of chemical compounds on
airway afferent nerves. In an attempt to focus the review,
we limit the discussion to literature that pertains to the
pharmacology of the afferent function of nerves (ie modu-
lation of excitability and action potential discharge). This
means that three other important areas of airway afferent
nerve pharmacology are excluded from this review: the
pharmacology of neuropeptide secretion from C-fibers in
the airways [1]; the pharmacology of the synapse
between the central terminals of airway afferent nerve
endings and secondary neurons in the CNS; and the
pharmacology of the developmental aspects and neuro-
plasticity of afferent neurons. In addition, we do not con-
sider the important topic of nasal-pharyngeal afferent
nerves in the present review [2].
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Experimental approaches in the study of
airway afferent pharmacology
In assessing the pharmacology of the afferent nerve per
se, it would be useful to evaluate directly the nerve
endings within the airway wall. Regrettably, these nerve
endings cannot be directly accessed with current micro-
electrophysiologic techniques. Information on the pharma-
cology of airway afferent nerve endings has been obtained
indirectly using the four basic approaches described
below. Each of the four designs has certain advantages
and disadvantages that must be considered before the
pharmacologic data can be interpreted appropriately.
Electrophysiologic studies of neuronal cell bodies
Although the airway afferent nerve endings are inaccessi-
ble to study by electrophysiologic methods, their cell
bodies can readily be investigated using standard patch-
clamp and intracellular electrophysiologic recording tech-
niques. The cell bodies of afferent fibers that innervate the
airway wall are located primarily in vagal ganglia (nodose
or jugular ganglia) [3]. Electrophysiologic investigation of
vagal ganglion neuron cell bodies has the advantage of
allowing for study of the pharmacology of afferent nerves,
free from secondary influences.
This technique, like any other, has limitations. First, the
extent to which the pharmacology observed at the cell body
reflects the pharmacology of the nerve ending is not known.
It is worth keeping in mind that the distance between an
afferent nerve ending in the human bronchi and its cell body
located in a vagal afferent ganglion is the equivalent of over
10,000 cell body diameters. The extent to which the myriad
signaling molecules, ion channels, and receptor proteins are
transported from the cell body to the nerve endings in the
airways is not known. Moreover, the spatial relationships of
signaling pathways is likely to be different in nerve terminals
as compared with the cell body. The second disadvantage
with this technique is that cell bodies situated in the vagal
ganglia are diverse with respect to the ionic currents they
express, and not only include those cell bodies with axons
that innervate the airways, but also those with axons that
innervate other thoracic and subdiaphramatic structures.
This disadvantage can be overcome to some extent by
using retrograde tracing technology, such that those cell
bodies with axons that project to the airways can be identi-
fied and studied [4].
Extracellular recording in isolated tissue
A close approximation of directly studying the nerve
ending in the airway wall makes use of the classical iso-
lated tissue design. In these studies, the trachea/bronchus
is isolated from the animal with the vagus nerves intact.
Using standard extracellular electrophysiologic recording
techniques, action potentials that arise from defined
receptive fields in the airway wall can be monitored as
they are conducted along the nerve fiber.
This approach has the advantage that chemical or non-
chemical stimuli can to be applied directly to that part of
the airway wall that contains the nerve endings (receptive
field). Another advantage of the isolated tissue design is
that the concentration of compounds bathing the nerve
endings within the tissue can be controlled.
A limitation of this design is that it is not possible to assess
directly the effect of chemicals on the membrane properties
of the afferent nerve that fall short of impulse generation. For
example, the influence of a compound that hyperpolarizes
the nerve ending, inhibits membrane hyperpolarization, or
depolarizes the membrane to a level that is subthreshold for
action potential generation would not be directly observed
with this preparation. However, the net influence of sub-
threshold changes can be indirectly assessed by evaluating
their influence on the frequency and number of action
potentials evoked from the nerve endings.
Extracellular recording in anesthetized animals
The most common experimental approach to studying
airway afferent nerve activity makes use of extracellular
recording techniques to detect action potentials traveling
in the vagus nerve in anesthetized animals in vivo. This
approach offers the advantage of studying reflex outputs
along with afferent activity while the nerves are in their
normal physiologic environment. Although this technique
is particularly well suited to the study of airway afferent
nerve physiology, the potential for indirect effects limits
the utility of this approach in studies of the direct pharma-
cology of airway afferent nerves.
Reflex outputs
The least direct approach makes use of reflex outputs as
the sole monitors of airway afferent activity. For example,
substances that cause cough or changes in breathing
pattern, independently of other changes in lung function,
can be deduced to act via afferent nerve pathways in the
airways. The disadvantage with this technique is that no
information on the nature of the afferent fiber type(s) that
initiate the reflex is obtained. This method is the only one
that has been used to obtain information on human airway
afferent nerve pharmacology.
Indirect pharmacology of airway afferent
nerves
Most if not all afferent nerves in the airway wall are sensi-
tive to mechanical perturbations [5–7]. Many of these are
low threshold mechanosensors (LTMs). The LTMs can be
segregated into those that rapidly adapt to prolonged
suprathreshold stimulation (rapidly adapting receptors
[RARs]) and those that slowly adapt to mechanical stimu-
lation (slowly adapting receptors [SARs]) [7]. Any sub-
stance that alters the normal mechanical forces in the lung
can potentially alter the activity of these fibers. Bron-
choconstriction is an example of an event that indirectlyRespiratory Research    Vol 2 No 4 Undem and Carr
leads to activation of LTMs [8–12]. In virtually all mammals
studied thus far inhalation of a smooth muscle spasmo-
gen, such as histamine, leads to action potential discharge
in RARs, and less commonly in SARs. If the bronchocon-
striction is minimized by pretreatment with a bronchodila-
tor, histamine-induced discharge in the LTMs is prevented
[11]. This suggests that histamine does not evoke action
potential discharge by directly acting on histamine recep-
tors in the airway afferent nerve endings. This conclusion
is supported by studies using the isolated, innervated
airway preparations [13,14].
It is often tacitly understood by pharmacologists that a
component of histamine-induced bronchospasm is sec-
ondary to afferent nerve-stimulated parasympathetic
reflexes. This is based on the observation that cholinergic
muscarinic receptor antagonists can inhibit histamine-
induced bronchoconstriction, an effect that is consistent
with the indirect stimulation of RARs. It should be recog-
nized, however, that the indirect activation of RARs and
increased parasympathetic reflex activity is not unique to
histamine. It is reasonable to assume that any bron-
choconstrictive agonist will lead to activation of RARs and
a consequent change in autonomic activity. Methacholine
is commonly used as a ‘direct smooth muscle spasmogen’
to study airway reactivity. It is often assumed that the
effect of methacholine on airflow resistance is indepen-
dent of the nervous system; however, as expected, several
studies [10,15] support the hypothesis that a component
of methacholine-induced bronchospasm is due to acetyl-
choline released from postganglionic parasympathetic
neurons that innervate airway smooth muscle. The contri-
bution made by neuronal reflexes may be increased in
inflammatory airway disease states, in which neuronal
activity is likely to be elevated [16].
Compounds need not contract airway smooth muscle to
activate afferent nerves indirectly. Substances that directly
affect the vasculature or lead to changes in lung compli-
ance can also alter the activity of afferent nerves [17].
Moreover, substances that lead to the release of auta-
coids may indirectly lead to changes in the activity of
chemosensitive afferent fibers in the airway (see below).
Considering the potential indirect manner in which the
activity of afferent nerves in the airway wall can be altered,
it may be a truism that any substance that affects lung
function will influence afferent nerve discharge and reflex
control of the airways.
Direct pharmacology of airway afferent
nerves
Ligand-gated ion channels
Synaptic neurotransmission typically occurs via the release
of a neurontransmitter that activates ‘receptors’ on postsy-
naptic dendrites. Most often the receptors are actually
ligand-gated ion channels. Opening of the ion channel
results in an increase in inward cation current and a mem-
brane depolarization. The prototypical example of this in the
peripheral nervous system is presynaptically released
acetylcholine acting on postsynaptic nicotinic receptors.
Although the peripheral processes of afferent nerves are not
activated directly by synaptic neurotransmission, anatomi-
cally they have long been recognized as specialized den-
drites [18]. It may not be surprising, therefore, that they
contain a variety of ligand-gated ion channels (Table 1).
Acetylcholine
The cholinergic nicotinic receptor is a pentameric protein
assembly that forms an ion channel by spanning the mem-
brane four times. The channel is relatively nonselective for
cations. There is histochemical evidence of nicotinic
receptors on a subpopulation of human vagal afferent gan-
glion neuron cell bodies [19]. In addition, stimulation of
nicotinic receptors on rabbit vagal afferent neuron cell
bodies is associated with an increase in nonselective
cation current, which is analogous to that seen in auto-
nomic ganglion neurons [20]. Evidence in favor of nico-
tinic receptors specifically on airway afferent nerve
endings is provided by the observations that inhaled ciga-
rette smoke-induced action potential discharge in canine
pulmonary C-fibers is inhibited by pretreatment with the
nicotinic receptor antagonist hexamethonium [21]. As pre-
dicted from these findings, respiratory reflexes such as
rapid shallow breathing or apnea evoked by cigarette
smoke are also inhibited by hexamethonium [22]. Also
consistent with the hypothesis of nicotinic receptors on
airway afferent nerves are results from psychometric
studies in humans [23] that showed that blockade of nico-
tinic receptors in the airways inhibits the sensation of irrita-
tion caused by cigarette smoke in normally nonsmoking
volunteers. The extent to which nicotine acts directly or
indirectly to stimulate airway afferent fibers cannot readily
be discerned from these in vivo studies.
5-Hydroxytryptamine
Among the large number of 5-hydroxytryptamine (5-HT)
receptor subtypes, the 5-HT3 subtype stands alone as a
ligand-gated ion channel. Like the nicotinic receptor, the
5-HT3 receptor spans the plasma membrane four times
and forms an ion pore that is relatively nonselective for
cations. Activation of 5-HT3 receptors causes substantial
membrane depolarizations and increases in ion conduc-
tances in most small-diameter (nociceptor-like) neuron
cell bodies in vagal ganglia [24]. 5-HT does not evoke
action potential discharge in afferent fibers in the guinea
pig isolated airway preparation [14]. However, that at
least some airway-specific neurons express 5-HT3 recep-
tors is supported by electrophysiologic studies [4] that
showed that 10 out of 12 neurons that were retrogradely
labeled by fluorescent dye injection into guinea pig
airways depolarized an average of over 8 mV in response
to 10 mmol/l 5-HT. 5-HT and phenybiguanide derivativeshave long been recognized as effective stimulants of
action potential discharge in bronchial and pulmonary C-
fibers when delivered to the lungs in vivo [25]. Although
there has been little attention given to the nature of the
receptor responsible for this effect, it is worth noting that
phenylbiguanide derivatives are selective for the 5-HT3
receptor subtype [26].
ATP and related purine nucleotides
Purines such as ATP can activate both metabotropic
receptors and ionotropic receptors. The ligand-gated ion
channels (ionotropic receptors) are referred to as P2X
receptors, and comprise subunits with only two trans-
membrane domains. There are at least seven subtypes of
P2X receptors, but interestingly P2X3 appears to be
localized nearly exclusively to a subset of small-diameter
(nociceptive-like) afferent neurons [27]. Neuronal cell
bodies in vagal ganglia express P2X2 and P2X3 recep-
tors [28], and P2X receptors have been identified on
afferent nerve processes that innervate airway neuroep-
ithelial bodies [28,29]. Stimulation of P2X receptors in
subpopulations of nodose ganglion neuron cell bodies
causes an increase in cation current across the plasma
membrane and brisk elevations in intracellular calcium
concentrations [30]. The characterization of P2X recep-
tors in nodose ganglion neurons is consistent with both
P2X2 and P2X3 receptors, and possibly with P2X2/3
heterodimers. The extent to which P2X receptor activa-
tion affects the membrane potential of airway-specific
neurons in vagal ganglia is not known.
Studies  in vivo [31] have demonstrated that ATP and
related purines stimulate action potential discharge in
canine pulmonary C-fibers by a mechanism that was inhib-
ited by P2X receptor-selective antagonists. ATP at con-
centrations as high as 100 mmol/l, however, does not
evoke action potential discharge in rapidly adapting LTMs
or C-fibers (unpublished observation) when applied
directly to their receptive fields in the guinea pig isolated
trachea/bronchus preparation.
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Table 1
Pharmacologic modulation of airway afferent nerve activity
Pharmacologic target Compounds Effect on activity or excitability
Ligand-gated ion channels
5-HT3 receptor 5-HT, phenylbiguanide ­
P2X receptor ATP ­
Nicotinic receptor Nicotine, acetylcholine ­
VR1 Capsaicin, resiniferatoxin, various acids ­
GPCRs
Histamine H1 receptor Histamine ­
Bradykinin B2 receptor Bradykinin ­
Adenosine A1 receptor Adenosine ­
Prostanoid receptors PGE2, PGD2, PGF2a, TXA2, PGI2 ­
Opioid m receptors Endomorphins, DAMGO ¯
Cys-LT1 receptors Cysteinyl leukotrienes ­
NK1, NK2 receptors Substance P, neurokinin A ­
Voltage-gated ion channels
Sodium channels Tetrodotoxin ¯
Lidocaine ¯
Veratridine ­
Amiloride ¯
Potassium channels 4-Aminopyridine ­
a-Dendrotoxin ­
NS1619 ¯
Iberiotoxin ­
Unknown targets
Ozone ­
Sulfur dioxide ­
Acetone ­
Water ­
Low-chloride solutions ­
Furosemide ¯­
Summary of compounds for which there is evidence for a direct effect on airway afferent nerve endings, or cell bodies. See text for more detail and
references. DAMGO, D-Ala2-Me-Phe4-Gly-ol5-enkephalin; NK, neurokinin; PG, prostaglandin; TX, thromboxane.Capsaicin (vallinoids)
Capsaicin stimulates airway C and Ad fibers that are high
threshold nociceptive-like mechanosensors in the airways
[13,14,32]. In guinea pigs and rats, capsaicin causes the
release of large quantities of neuropeptides in the airways
that effectively constrict guinea pig bronchial smooth
muscle [1] and cause plasma extravasation [33]. These
neuropeptide-induced effects probably lead to changes in
activity of low-threshold RAR or SAR nerve activity in an
indirect manner [34], as discussed above.
The first cloned receptor for capsaicin is termed vallinoid
receptor (VR)1 [35]. VR1 protein has been localized to
small-diameter (nociceptor-like) afferent neurons in dorsal
root, trigeminal, and vagal sensory ganglia. It is an ion
channel that is permeable to sodium and calcium ions and
is opened by heat, but the temperatures required for this
effect (>42°C) are not likely to be relevant to nerve
endings in the lower airways. There is a positive interaction
between protons and temperature [36], however, that may
result in activation of this channel in afferent nerves in the
airway wall. Thus, at a pH of 6.0, the channel is opened at
30°C. Consistent with this concept, the discharge of action
potentials induced by a applying a pH 5 solution to recep-
tive fields of afferent C-fibers in the guinea pig isolated
airway preparation was blocked by the VR1 antagonist
capsazepine [37]. Electrophysiologic studies on afferent
cell bodies, and on the cloned VR1 expressed in non-neu-
ronal cells support the hypothesis that various lipid media-
tors may serve as endogenous VR1 ligands. These include
the endogenous cannabinoid receptor agonist anandamide
[38], which was recently reported to stimulate C-fibers in
guinea pig airways [39], and 5-, 12- and 15-lipoxygnase
products of arachidonic acid [40].
The therapeutic potential of VR1 agonists such as cap-
saicin or resiniferatoxin is based on the ability of these
substances to ‘desensitize’ afferent neurons that express
VR1. These ligands not only desensitize the afferent
neurons to further activation via VR1 channels, but also
lead to nonselective ‘heterologous’ desensitization such
that the nerve becomes unresponsive to other stimuli that
would normally evoke action potential discharge. The
mechanism of heterologous desensitization through VR1
has not been elucidated in detail, but probably involves an
inhibition of voltage-gated sodium channels [41].
G-protein-coupled receptor agonists
There are a number of G-protein-coupled receptor
(GPCR) agonists that, through various second messenger
systems, can affect the function of airway afferent nerves
(Table 1). Although not specifically studied in airways
afferent neurons, several agonists may affect both ligand-
gated ion channel and GPCRs. For example, in addition to
cholinergic nicotinic receptors on afferent nerves (as dis-
cussed above), there is evidence of cholinergic muscarinic
M2 and M3 receptors on afferent neuronal cell bodies in
the dorsal root ganglia [42]. Likewise, in vagal afferent
neuronal cell bodies, 5-HT can interact with both 5-HT3
ion channels and G-protein-coupled 5-HT receptors [43].
Bradykinin
Bradykinin is one of the few GPCR agonists that consis-
tently lead to action potential discharge when applied
directly to the receptive fields of guinea pig airway afferent
neurons [14,44]. This effect of bradykinin is blocked by the
B2-receptor-selective antagonist HOE140, and is selective
for C and Ad nociceptive-like fibers [44]. The ionic mecha-
nism that underlies B2-receptor-mediated activation of
airway afferent nerve fibers is unknown. Bradykinin B2
receptor stimulation depolarizes the membrane potential of
nodose ganglion neuron cell bodies, and inhibits a calcium-
dependent potassium current that is responsible for an
after-spike hyperpolarization [45]. Both of these effects are
mediated by bradykinin B2 receptors, although the latter
effect on the after-spike hyperpolarization appears to be
secondary to prostacyclin production by the neuron.
Bradykinin stimulated action potential discharge in airway
C-fiber and RAR afferent nerves in several species studied
in vivo [32,46]. In some studies, however, the effect of
bradykinin on RAR fibers appeared to be secondary to
prostaglandin-mediated changes in lung mechanics.
Bradykinin B2 receptors have been localized autoradi-
ographically in human nodose ganglion cell bodies [47],
and bradykinin causes sneezing and coughing when
applied to appropriate sites in human airways [48,49].
Histamine
Histamine H1 receptor activation results in membrane
depolarization of a subpopulation of vagal afferent neuron
cell bodies from a variety of species. Unlike ligand-gated
ion channel agonists and bradykinin, the membrane depo-
larization evoked by histamine is typically associated with
a decrease in ion conductance [50,51]. Histamine
inhibits the resting or so-called ‘leak’ potassium current in
nodose ganglion neuronal cell bodies, and in vagal gan-
glion cell bodies from some species it inhibits voltage-
gated calcium currents and the calcium-activated
potassium current that subserves after-spike hyperpolar-
izations [51,52]. These types of effects on afferent
neurons indicate that histamine alone may not directly
evoke action potential discharge in airway afferent
endings. Consistent with this prediction, histamine does
not evoke action potential discharge in vagal afferent
fibers innervating guinea pig isolated airway preparations
[13,14]. Histamine effectively stimulates RAR and SAR
fibers when studied in vivo, but the preponderance of evi-
dence supports the hypothesis that this effect is sec-
ondary to the effects of histamine on the vasculature or
lung mechanics (see above). Studies on vagal ganglion
neuron cell bodies that revealed an inhibition of various
potassium currents suggest that histamine may increase
Respiratory Research    Vol 2 No 4 Undem and Carrthe excitability of airway afferent nerves. Indeed, hista-
mine has been shown to increase the mechanical and
chemical (capsaicin) sensitivity of afferent C-fibers in dog
airways [53].
Although substances that affect afferent nerve activity can
be categorized as those that act directly and those that
act indirectly, it should not go unnoticed that many sub-
stances act in both a direct and indirect manner. Hista-
mine may be considered a prototypical example. By
causing bronchospasm, histamine H1 receptor activation
can indirectly lead to activation of mechanosensitive affer-
ent fibers in the airway wall. In addition, the excitability of
some of these same fibers may be increased by the direct
inhibitory action of histamine receptor activation on various
ion channels that are present in afferent nerve terminals.
Thus, for any given amount of bronchospasm, the action
potential discharge may be greater for a substance such
as histamine that has both indirect and direct actions on
the nerve than for an agent that only indirectly influences
afferent neuron activity by contracting the airway.
Eicosanoids
Prostaglandins have long been recognized to activate or
increase the excitability of afferent nerves. Electrophysio-
logic studies on vagal afferent ganglion neuron cell bodies
have demonstrated excitatory affects of several
prostaglandins, including prostaglandin E2, D2, and I2
(prostacyclin) [50,54]. Little attention has been given to
prostaglandin receptor pharmacology in these studies,
although EP3 receptors have been immunohistochemi-
cally identified on rat nodose ganglion neuron cell bodies
[55]. Prostaglandins have been found to inhibit calcium-
activated potassium currents that are involved in the after-
spike hyperpolarization, and can lead to an increase in the
hyperpolarization-activated cation current (Ih) [56]. If these
effects occur at the nerve terminals, they would probably
lead to an increase in the peak frequency of action poten-
tial discharge. Consistent with this, in vivo studies [58]
revealed that low concentrations of prostaglandin E2 did
not cause action potential discharge in rat airway afferent
nerves, but effectively sensitized pulmonary C-fiber affer-
ents to capsaicin or mechanical stimulation during lung
inflation. Others have noted that thromboxane, and
prostaglandin E2, I2 and F2a increased the rate of baseline
discharge in airway RAR and C-fibers [34,58–61]. In
support of a role for prostaglandins in increasing the
excitability of human airway afferent C-fibers are the find-
ings that inhalation of prostaglandin E2 and prostaglandin
F2a increased the sensitivity of the cough response in
human volunteers [62].
There has been little investigation into the potential role of
cysteinyl leukotrienes (cys-LTs) on airway afferent nerve
activity. Inhalation of leukotriene C4 causes activation of
RAR fibers in guinea pig airways, but this may be sec-
ondary to bronchoconstriction [12]. Cyst-LTs inhibited the
after-spike hyperpolarization in vagal sensory ganglion
neuron cell bodies, and caused membrane depolarization
of identified airway neuron cell bodies isolated from vagal
afferent ganglia [50,63]. This latter effect is due to an inhi-
bition of a resting potassium current, and is blocked by the
cys-LT1 receptor antagonist zafirlukast. Other lipoxyge-
nase products, as discussed above, may interact directly
with the VR1 channel on nociceptive-like nerve terminals
in the airways.
Adenosine
Adenosine increases action potential discharge in rat pul-
monary C-fibers [64]. This effect did not appear to involve
adenosine A2 receptors, but was inhibited by the A1
receptor-selective antagonist 1,3-dipropyl-8-cyclopentyl-
xanthine. In human volunteers inhalation of AMP was
found to cause a greater dyspneic response than metha-
choline when normalized to change in forced expiratory
volume in 1 s, suggesting increased afferent activity in
sensory nerves [65].
Neurokinins
Depending on the species, neurokinin 1 receptor agonists
have been found to depolarize [66] or hyperpolarize [67]
the membrane potential of nodose ganglion neuron cell
bodies. The hyperpolarization of ferret nodose ganglion
neurons is secondary to activation of a calcium-gated
potassium current [67]. Neurokinin 2 receptor agonists
depolarize guinea pig nodose ganglion cell bodies sec-
ondary to an increase in a nonselective cation current
[68]. Interestingly, this effect is ‘unmasked’ by inflamma-
tory mediators. Thus, none of 156 nodose ganglion
neuron cell bodies from control guinea pigs depolarized in
response to neurokinin 2 receptor activation. In contrast,
within a day of allergen challenge of the airways, >80% of
the nodose ganglion cell bodies responded to neurokinin
2 agonists with membrane depolarization [68].
Substance P leads to discharge of RAR fibers in rabbit
[69] and guinea pig airways [70]. This does not appear to
be a direct effect of the neurokinin on the RAR fiber. In
rabbits, the increase in RAR activity was associated with
microvascular leakage in the lungs, and in the guinea pig
the substance P-induced discharge in RAR activity was
inhibited by nitric oxide synthase inhibitors.
Opioids
The m opioid receptor agonists inhibit voltage-gated ion
calcium currents in a subpopulation of vagal afferent
neurons [71]. In guinea pig nodose ganglion neuron cell
bodies, the m opioid agonist Tyr-D-Ala-Gly-MePhe-Gly-ol
enkephalin had no affect on resting membrane current or
on the Ih, but inhibited the ability of other inflammatory
mediators to enhance Ih [72]. Thus, opioids may inhibit
the increased excitability of afferent nerves induced by
Available online http://respiratory-research.com/content/2/4/234
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may modulate airway afferent nerves is supported by
studies on reflex physiology, in which m, d and s opioid
agonists acting in the airways can lead to an inhibition of
respiratory reflexes [74,75]. The extent to which their
inhibitory effects are due to action on the airway afferent
endings is not clear.
Ion channel modulators
Sodium channel pharmacology
All afferent nerves require voltage-gated sodium channels
for the conduction of action potentials from the regenera-
tive region of their nerve terminals to the CNS. The most
commonly studied inhibitors of voltage-gated sodium
channels in the airways has been lidocaine and related
local anesthetics. Early studies with these compounds led
to the hypothesis that the generator potential caused by
mechanical activation of the nerve terminal was not
affected (or only modestly affected) by local anesthetic
action, whereas the ability of the generator potential to
evoke regenerative action potentials was blocked [76].
Tetrodotoxin is a potent inhibitor of a subset of voltage-
gated sodium channels. Blocking tetrodotoxin-sensitive
sodium channels prevents conduction in all airway afferent
nerve fibers studied thus far. There are voltage-gated
sodium channels that are not blocked by tetrodotoxin,
which are termed tetrodotoxin-resistant (TTX-R) channels.
At least two types of TTX-R sodium channels have been
found to be preferentially localized to afferent nerves [77].
These ‘sensory nerve-specific’ (SNS) channels are found
mainly in small-diameter (nociceptor-like) neurons in affer-
ent ganglia, supporting the idea that they play more of a
role in nociceptive fibers than in LTM fibers. The nomen-
clature of SNS sodium channels is rather confusing, with
SNS1 also referred to as PN3, NaNG or Nav1.8, while
SNS2 is sometimes referred to as the NaN, SNS2, PN5,
NaT, SCN12A or Nav1.9 channel. Nociceptive-like afferent
nerves that innervate guinea pig airways are derived from
cell bodies that are located primarily in the jugular
(superior vagal) ganglia [13]. Christian and Togo [78]
noted that the vast majority of neurons in the jugular
ganglia have sufficient TTX-R sodium channels to support
action potential generation. Although there are no reports
of TTX-R channel specifically on airway afferent nerves,
preliminary data from our laboratory [79] have shown that
jugular neuron cell bodies retrogradely labeled by dye
injection into the guinea pig trachea have sufficient TTX-R
current to support action potential formation. The TTX-R
sodium channels may be relevant to airway afferent phar-
macology, because in the somatosensory system sub-
stances such as prostaglandin E2, that increase excitability
of C-fiber neurons, also increase the current through the
TTX-R channels [80]. Although drugs have been devel-
oped that block both tetrodotoxin-sensitive sodium chan-
nels and TTX-R sodium channels [81], there are no
pharmacologic tools available that allow for the selective
inhibition of the TTX-R current in sensory neurons.
Veratrum alkaloids were used to activate bronchial and
pulmonary afferent nerves, long before their mechanism of
action was understood [82]. Veratridine is now known to
interact selectively with voltage-gated sodium channels,
although it neither opens the channel directly nor blocks
the channel. Rather, it is believed to act by inhibiting the
inactivation of the channel [83]. In any event, this class of
drugs is one the few that leads to activation of all types of
airway afferent nerves.
It is generally believed that mechanically sensitive afferent
fibers, including those that innervate the airways, express
mechanically gated ion channels at their peripheral termi-
nals, and that these channels serve as mechanotransduc-
ers (ie convert mechanical energy into a form that can be
encoded into action potentials). Although the exact iden-
tity of the mechanosensor(s) is unknown, a variety of evi-
dence suggests that epithelial sodium channels (ENaCs)
may act as mechanotransducers in primary afferent
neurons [84–87]. In particular, the ENaC channel block-
ers amiloride and benzamil were shown to inhibit pres-
sure-evoked baroreceptor afferent nerve activity [85] and
renal nerve activity evoked by increases in renal pelvic
pressure [88]. With respect to the airways, amiloride and
benzamil were shown to reduce the mechanical activation
of guinea pig trachea/bronchus afferent neurons, but this
did not appear to occur by a selective blockade of ENaCs
or ion channels involved in mechanotransduction, but
rather appeared to be secondary to a reduction in neu-
ronal excitability caused by blockade of voltage-gated
sodium currents [89].
Potassium channel pharmacology
There is surprisingly little information published on the
effect of potassium channel-modifying drugs on the affer-
ent activity of airway sensory nerves. Voltage-gated potas-
sium channels that are involved in ‘A’ currents (rapidly
inactivating potassium currents) can be inhibited by
4-aminopyridine and a-dendrotoxin. These compounds
have been found to depolarize the resting membrane
potential of identified guinea pig airway nodose ganglion
neurons [90]. Moreover, applying these A-current inhibitors
to the guinea pig isolated airway evokes a burst of action
potentials in LTMs, as well as nociceptive-like airways affer-
ent fibers. These findings suggest that a potassium current
carried by these channels is responsible for keeping the
membrane potential of airway afferent nerves below the
threshold for action potential generation. Selective
inhibitors of the maxi-K current, such as iberiotoxin, do not
affect the resting membrane potential of airway afferent
nerves [90]. However, in guinea pig airways the maxi-K
channel opener NS1619 did inhibit the hyperosmolar-
induced activation of vagal Ad-fibers and bradykinin-
Respiratory Research    Vol 2 No 4 Undem and Carrinduced activation of C-fibers [91]. Consistent with these
in vitro observations, NS 1619 effectively inhibited the
cough reflex induced by bradykinin in guinea pigs [91].
Chloride and calcium channel pharmacology
g-Aminobutyric acid caused a membrane depolarization in
10 out of 12 identified guinea pig airway nodose ganglion
neurons [4]. This effect probably occurs through increas-
ing current through chloride channels. These studies
suggest, at least at the cell body, that the reversal poten-
tial for chloride ions is positive to the resting potential,
such that opening the channels leads to chloride efflux
from the cell and membrane depolarization. Consistent
with this hypothesis is that isotonic solutions containing
low chloride concentrations evoked action potential dis-
charge in a subpopulation of guinea pig airway LTM
A-fibers and C-fibers [92], and activated canine laryngeal
afferent fibers [93]. Low chloride solutions also cause
cough in humans [94]. Furosemide modestly inhibits
action potential discharge in airway afferent fibers and the
cough reflex caused by low chloride solutions, but the
mechanism underlying this has not yet been elucidated
[92,93,95]. Similarly, the mechanism(s) of furosemide-
induced alleviation of experimentally induced dyspnea [96]
or furosemide-induced sensitization of SARs and desensi-
tization of RARs in rat airways [97] is unknown.
The voltage-gated calcium current in guinea pig vagal affer-
ent jugular ganglion cell bodies is due to a composite of N-,
L-, and P-type calcium channels [52]. Compounds that
block N-type calcium channels, such as w-conotoxin, inhibit
neuropeptide secretion from primary afferent nerves in
guinea pig bronchi [98], but the effect of this compound or
other calcium channel antagonists on action potential dis-
charge or pattern in airway afferent nerves is not known.
Environmental stimuli
A variety of environmental irritants lead to action potential
discharge in airway afferent nerves (Table 1). The noci-
ceptive class of fibers and RAR fibers are particularly
sensitive to activation by various inhaled pollutants.
Ozone has been found to increase the excitability of
airway RARs [99] and C-fibers [100], such that the
threshold for their mechanical and chemical activation is
reduced. There have been no studies published on the
direct effect of ozone on the electrophysiologic proper-
ties of sensory neurons.
Allergen challenge in vivo leads to activation of airway
afferent nerves [101,102]. Allergen exposure in vitro
increases the sensitivity of Ad nerve endings in the guinea
pig isolated trachea/bronchus to mechanical stimulation
[103]. Exposing the nodose ganglia isolated from immu-
nized guinea pig to allergen leads to activation of resident
mast cells, and decreases in the resting potassium current
and certain calcium-activated potassium currents [104].
Low pH solutions can induce action potential discharge in
airway afferent nerve fibers [37]. With respect to nocicep-
tive-like fibers, this effect is most likely due to increasing
cation current through VR1 channels (see above). Other
vagal afferent neurons may also respond to decreases in
pH [105] via activation of various acid-sensing ion chan-
nels. It is likely that an increase in proton concentration
near the airway sensory terminals, and the consequent
increase in cation current through acid-sensing ion chan-
nels, is the mechanism by which compounds such as citric
acid and sulfur dioxide initiate cough and other respiratory
reflexes [94,106].
Conclusion
A composite image of airway afferent neuropharmacology
is emerging from classical studies on reflex physiology and
single-unit recording of vagal afferent nerves, in combina-
tion with electrophysiologic studies of vagal ganglion
neuron cell bodies. The vast majority of afferent nerves
that innervate the airway wall are mechanosensory, in that
they respond with a discharge of action potentials to
deformation of the receptive field. Therefore, any sub-
stance that changes the mechanical environment (eg bon-
choconstrictors, bronchodilators, and vasoactive
substances) will influence afferent nerve activity arising
from the airways. Substances that affect the osmolarity or
pH in the environment of the sensory nerve endings will
also change activity in a subset of acid-sensing and osmo-
larity-sensing afferent fibers. Agonists such as 5-HT,
acetylcholine, ATP, and capsaicin can directly interact
with ionotropic receptors in airway afferent nerve fibers,
leading to membrane depolarization and action potential
discharge. Other agonists can interact with GPCRs on
airway afferent nerves in a manner that does not activate
the fiber, but modulates its excitability in response to
mechanical or chemical stimuli. Finally, ion channel-modify-
ing compounds can increase or decrease ionic current
through voltage-gated ion channels in airway afferent
nerves, to affect afferent activity.
Based on these observations one may conclude that most
substances that enter the airways and affect lung function
will affect afferent nerve activity directly, and/or indirectly,
thereby altering the communication between the airways
and the CNS. This, in turn, will lead to changes in auto-
nomic and respiratory reflex activity.
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